Proclara Obtains U.S. Patents for Technology Targeting Protein-misfolding Disorders Such as Alzheimer’s

Proclara Obtains U.S. Patents for Technology Targeting Protein-misfolding Disorders Such as Alzheimer’s
Proclara Biosciences has announced two additional patents in its effort to develop therapies for neurodegenerative diseases such as Alzheimer’s that have been linked to protein misfolding. A key step in the biotech company’s approach  to treating these diseases was discovering a protein motif which recognizes that several toxic misfolded proteins, including Aβ, tau and a-synuclein, share

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *